10940

532488

DIVISLAB

img img img img
No Data Available

Experience smart and hassle-free investing in minutes with Bajaj Broking! *T&C apply

DIVI S LABORATORIES LTD Share Price Today

DIVI S LABORATORIES LTD is currently trading at ₹6638.5, down by ₹114.5 from the previous close. The stock touched an intraday high of ₹6815.00 and a low of ₹6610.00 during the latest trading session. Over the past one year, DIVI S LABORATORIES LTD has delivered a loss of 1.68%, while the stock has declined 2.82% in the last one month.

DIVI S LABORATORIES LTD performance

Today’s low Today’s high
₹ 6610.00 ₹ 6815.00
₹ 6638.50
52 week low 52 week high
₹ 5636.50 ₹ 7071.50
₹ 6638.50
Open Price ₹ 6750.00
Prev. Close ₹ 6753.00
Volume (Shares) 405743.00
Total traded value ₹ 26935.24
Upper Circuit ₹ 7428.00
Lower Circuit ₹ 6078.00
info

Investment Returns

Over 1 Month -2.82% Over 3 Months 3.01% Over 6 Months 3.04% Over 1 Year -1.68%
demotext Smart Investing Starts here ! Trade Smart with Fast Execution & Zero Account Opening Fees Invest Now

DIVI S LABORATORIES LTD fundamentals


  • Market cap (Cr) 1,76,231.30
  • P/E Ratio (TTM) 68.80
  • Beta 0.60
  • Book Value / share 629.49
  • Return on equity 15.57%
  • EPS (TTM) 100.29
  • Dividend yield 0.44%
  • Net profit/quarter (Cr) 756.00
info icon alternate text
  • Market cap (Cr) 1,76,241.90
  • P/E Ratio (TTM) 68.80
  • Beta 0.53
  • Book Value / share 629.49
  • Return on equity 15.57%
  • EPS (TTM) 100.29
  • Dividend yield 0.44%
  • Net profit/quarter (Cr) 756.00
info icon alternate text

DIVI S LABORATORIES LTD Financials

  • Key Results
  • Key Ratios
  • Balance sheet
  • Cash Flow
  • Competition
info-icon
Revenue
Net income
Particulars MAR 2026 (Values in Cr)
Revenue 2793.00
Operating Expense 1976.00
Net Profit 756.00
Net Profit Margin (%) 27.06
Earnings Per Share (EPS) 28.44
EBITDA 1097.00
Effective Tax Rate (%) 22.14
Particulars DEC 2025 (Values in Cr)
Revenue 2578.00
Operating Expense 1793.00
Net Profit 598.00
Net Profit Margin (%) 23.19
Earnings Per Share (EPS) 22.56
EBITDA 920.00
Effective Tax Rate (%) 25.06
Particulars SEP 2025 (Values in Cr)
Revenue 2660.00
Operating Expense 1886.00
Net Profit 696.00
Net Profit Margin (%) 26.16
Earnings Per Share (EPS) 26.24
EBITDA 1041.00
Effective Tax Rate (%) 24.34
Particulars JUN 2025 (Values in Cr)
Revenue 2357.00
Operating Expense 1729.00
Net Profit 557.00
Net Profit Margin (%) 23.63
Earnings Per Share (EPS) 20.95
EBITDA 862.00
Effective Tax Rate (%) 25.43
Particulars MAR 2025 (Values in Cr)
Revenue 2536.00
Operating Expense 1762.00
Net Profit 667.00
Net Profit Margin (%) 26.30
Earnings Per Share (EPS) 25.12
EBITDA 968.00
Effective Tax Rate (%) 22.53
Particulars MAR 2026 (Values in Cr)
Revenue 10388.00
Operating Expense 7384.00
Net Profit 2607.00
Net Profit Margin (%) 25.09
Earnings Per Share (EPS) 98.19
EBITDA 3920.00
Effective Tax Rate (%) 24.12
Particulars MAR 2025 (Values in Cr)
Revenue 9198.00
Operating Expense 6621.00
Net Profit 2209.00
Net Profit Margin (%) 24.01
Earnings Per Share (EPS) 83.20
EBITDA 3331.00
Effective Tax Rate (%) 24.58
Particulars MAR 2024 (Values in Cr)
Revenue 7665.00
Operating Expense 5870.00
Net Profit 1576.00
Net Profit Margin (%) 20.56
Earnings Per Share (EPS) 59.37
EBITDA 2511.00
Effective Tax Rate (%) 26.07
Particulars MAR 2023 (Values in Cr)
Revenue 7625.00
Operating Expense 5620.00
Net Profit 1808.00
Net Profit Margin (%) 23.71
Earnings Per Share (EPS) 68.11
EBITDA 2697.00
Effective Tax Rate (%) 23.19
Particulars MAR 2022 (Values in Cr)
Revenue 8879.82
Operating Expense 5314.55
Net Profit 2948.54
Net Profit Margin (%) 33.20
Earnings Per Share (EPS) 111.07
EBITDA 3987.72
Effective Tax Rate (%) 19.80
Particulars MAR 2025 (Values in Cr)
Book Value / Share 564.87
ROE % 15.35
ROCE % 20.42
Total Debt to Total Equity 0.00
EBITDA Margin 35.48
Particulars MAR 2024 (Values in Cr)
Book Value / Share 512.11
ROE % 12.15
ROCE % 16.41
Total Debt to Total Equity 0.00
EBITDA Margin 32.44
Particulars MAR 2023 (Values in Cr)
Book Value / Share 480.96
ROE % 14.89
ROCE % 19.30
Total Debt to Total Equity 0.00
EBITDA Margin 34.94
Particulars MAR 2022 (Values in Cr)
Book Value / Share 441.82
ROE % 28.16
ROCE % 34.96
Total Debt to Total Equity 0.00
EBITDA Margin 44.61
Particulars MAR 2021 (Values in Cr)
Book Value / Share 350.15
ROE % 23.90
ROCE % 31.97
Total Debt to Total Equity 0.00
EBITDA Margin 41.95
Particulars MAR 2025 (Values in Cr)
Book Value / Share 562.08
ROE % 15.57
ROCE % 20.63
Total Debt to Total Equity 0.00
EBITDA Margin 36.23
Particulars MAR 2024 (Values in Cr)
Book Value / Share 508.83
ROE % 12.04
ROCE % 16.27
Total Debt to Total Equity 0.00
EBITDA Margin 32.77
Particulars MAR 2023 (Values in Cr)
Book Value / Share 479.43
ROE % 14.82
ROCE % 19.27
Total Debt to Total Equity 0.00
EBITDA Margin 35.38
Particulars MAR 2022 (Values in Cr)
Book Value / Share 440.44
ROE % 28.13
ROCE % 35.01
Total Debt to Total Equity 0.00
EBITDA Margin 44.92
Particulars MAR 2021 (Values in Cr)
Book Value / Share 349.28
ROE % 23.57
ROCE % 31.55
Total Debt to Total Equity 0.00
EBITDA Margin 42.43
Particulars MAR 2025 (Values in Cr)
Cash & Short Term Investments 3715.00
Total Assets 16932.00
Total Liabilities 16932.00
Total Equity 14969.00
Share Outstanding 26
Price to Book Ratio 10.27
Return on Assets (%) 12.93
Return on Capital (%) 14.63
Particulars MAR 2024 (Values in Cr)
Cash & Short Term Investments 3980.00
Total Assets 15470.00
Total Liabilities 15470.00
Total Equity 13571.00
Share Outstanding 26
Price to Book Ratio 6.75
Return on Assets (%) 10.34
Return on Capital (%) 11.79
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 4213.09
Total Assets 14438.77
Total Liabilities 14438.77
Total Equity 12767.09
Share Outstanding 26
Price to Book Ratio 5.89
Return on Assets (%) 12.62
Return on Capital (%) 14.28
Particulars MAR 2022 (Values in Cr)
Cash & Short Term Investments 2818.88
Total Assets 13374.71
Total Liabilities 13374.71
Total Equity 11728.18
Share Outstanding 26
Price to Book Ratio 10.00
Return on Assets (%) 22.13
Return on Capital (%) 25.24
Particulars MAR 2021 (Values in Cr)
Cash & Short Term Investments 2156.03
Total Assets 10774.07
Total Liabilities 10774.07
Total Equity 9294.61
Share Outstanding 26
Price to Book Ratio 10.39
Return on Assets (%) 18.41
Return on Capital (%) 21.35
Particulars MAR 2025 (Values in Cr)
Cash & Short Term Investments 3696.00
Total Assets 16824.00
Total Liabilities 16824.00
Total Equity 14895.00
Share Outstanding 26
Price to Book Ratio 10.27
Return on Assets (%) 13.13
Return on Capital (%) 14.83
Particulars MAR 2024 (Values in Cr)
Cash & Short Term Investments 3961.00
Total Assets 15362.00
Total Liabilities 15362.00
Total Equity 13484.00
Share Outstanding 26
Price to Book Ratio 6.75
Return on Assets (%) 10.25
Return on Capital (%) 11.69
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 4188.00
Total Assets 14352.00
Total Liabilities 14352.00
Total Equity 12705.00
Share Outstanding 26
Price to Book Ratio 5.89
Return on Assets (%) 12.59
Return on Capital (%) 14.23
Particulars MAR 2022 (Values in Cr)
Cash & Short Term Investments 2803.68
Total Assets 13307.86
Total Liabilities 13307.86
Total Equity 11691.35
Share Outstanding 26
Price to Book Ratio 10.00
Return on Assets (%) 22.15
Return on Capital (%) 25.22
Particulars MAR 2021 (Values in Cr)
Cash & Short Term Investments 2142.01
Total Assets 10723.77
Total Liabilities 10723.77
Total Equity 9271.57
Share Outstanding 26
Price to Book Ratio 10.39
Return on Assets (%) 18.22
Return on Capital (%) 21.08
Particulars MAR 2025 (Values in Cr)
Net Income 2916.00
Cash from Operations 2477.00
Cash from Investing -804.00
Cash from Financing -799.00
Net change in Cash 50.00
Free Cash Flow 3915.00
Particulars MAR 2024 (Values in Cr)
Net Income 2163.00
Cash from Operations 1637.00
Cash from Investing -269.00
Cash from Financing -799.00
Net change in Cash 193.00
Free Cash Flow 2640.00
Particulars MAR 2023 (Values in Cr)
Net Income 2368.63
Cash from Operations 2932.38
Cash from Investing -2707.62
Cash from Financing -797.17
Net change in Cash -1045.06
Free Cash Flow 3405.40
Particulars MAR 2022 (Values in Cr)
Net Income 3683.50
Cash from Operations 2552.78
Cash from Investing -2194.92
Cash from Financing -532.44
Net change in Cash -815.56
Free Cash Flow 3265.98
Particulars MAR 2021 (Values in Cr)
Net Income 2666.04
Cash from Operations 2591.25
Cash from Investing 75.13
Cash from Financing -34.89
Net change in Cash 1987.17
Free Cash Flow 3501.44
Particulars MAR 2025 (Values in Cr)
Net Income 2929.00
Cash from Operations 2468.00
Cash from Investing -803.00
Cash from Financing -797.00
Net change in Cash 50.00
Free Cash Flow 3905.00
Particulars MAR 2024 (Values in Cr)
Net Income 2132.00
Cash from Operations 1639.00
Cash from Investing -268.00
Cash from Financing -798.00
Net change in Cash 200.00
Free Cash Flow 2641.00
Particulars MAR 2023 (Values in Cr)
Net Income 2354.10
Cash from Operations 2919.54
Cash from Investing -2706.75
Cash from Financing -796.59
Net change in Cash -1055.39
Free Cash Flow 3391.69
Particulars MAR 2022 (Values in Cr)
Net Income 3676.52
Cash from Operations 2539.95
Cash from Investing -2195.40
Cash from Financing -531.50
Net change in Cash -816.74
Free Cash Flow 3253.62
Particulars MAR 2021 (Values in Cr)
Net Income 2627.87
Cash from Operations 2580.01
Cash from Investing 75.34
Cash from Financing -33.97
Net change in Cash 1988.42
Free Cash Flow 3489.99
Company Name Price P/E P/B Market Cap 52 Week Low 52 Week High
AMBALAL SARABHAI ENT L 34.24 14.15 1.65 262.39 23.12 38.85
BLISS GVS PHARMA LTD 419.15 33.91 3.71 4434.14 118.35 462.70
CIPLA LTD 1388.25 29.46 3.25 112149.13 1165.55 1672.20
FERMENTA BIOTECH LTD. 341.00 15.04 2.46 1003.60 256.40 399.00
Company Name Price P/E P/B Market Cap 52 Week Low 52 Week High
AMBALAL SARABHAI ENT L 34.24 23.94 4.41 262.39 23.12 38.85
AMRUTANJAN HEALTH CARE LTD. 554.85 24.87 4.33 1604.11 490.00 789.95
ASTRAZENECA PHARMA INDIA LTD. 8383.40 109.49 24.01 20958.50 7630.00 10653.05
BLISS GVS PHARMA LTD 419.15 45.07 3.83 4434.14 118.35 462.70

DIVI S LABORATORIES LTD shareholding pattern

Holding
8.6%
51.88%
20.29%
19.21%
Name Shares Category
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)

News

Left Arrow
Right Arrow

DIVI S LABORATORIES LTD Technicals Summary

  • EMA & SMA
  • Resistance and Support
  • Delivery and Volume
  • Beta
  • Price Change Analysis
6638.50 -1.69 redarrow
red-green-graph indicator
7 Bearish
9 Bullish
  • 5 Days 6639.70
  • 26 Days 6634.10
  • 10 Days 6651.80
  • 50 Days 6535.60
  • 12 Days 6657.80
  • 100 Days 6432.10
  • 20 Days 6654.80
  • 200 Days 6333.10
6579.00 PIVOT
First Support 6448.00 First Resistance 6652.00 Second Support 6375.00 Second Resistance 6783.00 Third Support 6244.00 Third Resistance 6856.00
RSI 43.83 ADX 18.54 MACD 15.79 Williams % R -86.18 Commodity Channel Index (CCI) -97.25
Date 2026-06-08 Week 216642.00 Same Day 279913.00 Month 217828.00
1 Year 0.60 3 Year 0.60
Over 1 Month
-2.82% down
Over 1 Year
-1.68% down
Over 3 Months
3.01% down
Over 3 Years
23.05% down
Over 6 Months
3.04% down
Over 5 Years
8.98% down

DIVI S LABORATORIES LTD Corporate Actions

Dividend date Dividend amount Dividend type Record date Instrument type
24 Jul 2026 30.0 Final 24 Jul 2026 Equity shares
25 Jul 2025 30.0 Final 25 Jul 2025 Equity shares
02 Aug 2024 30.0 Final 02 Aug 2024 Equity shares
11 Aug 2023 30.0 Final 11 Aug 2023 Equity shares
11 Aug 2022 30.0 Final 12 Aug 2022 Equity shares
17 Aug 2021 20.0 Final 20 Aug 2021 Equity shares
25 Feb 2020 16.0 Interim 26 Feb 2020 Equity shares
14 Aug 2019 16.0 Final 17 Aug 2019 Equity shares
31 Aug 2018 10.0 Final 04 Sep 2018 Equity shares
15 Sep 2017 10.0 Final 19 Sep 2017 Equity shares
17 Mar 2016 10.0 Interim 18 Mar 2016 Equity shares
06 Aug 2015 20.0 Final 10 Aug 2015 Equity shares
31 Jul 2014 20.0 Final 04 Aug 2014 Equity shares
25 Jul 2013 15.0 Final 29 Jul 2013 Equity shares
26 Jul 2012 13.0 Final 30 Jul 2012 Equity shares
16 Jun 2011 10.0 Final 18 Jun 2011 Equity shares
02 Jul 2010 6.0 Final 06 Jul 2010 Equity shares
15 Jun 2009 6.0 Final 17 Jun 2009 Equity shares
26 Jun 2008 4.0 Final 28 Jun 2008 Equity shares
23 Mar 2007 2.0 Interim 26 Mar 2007 Equity shares
11 Aug 2005 0.0 Final 13 Aug 2005 Equity shares
Ex-Date Ex-Bonus Ratio
26 Sep 2015 23 Sep 2015 1:1
01 Aug 2009 30 Jul 2009 1:1
Ex-Date Old FV NEW FV Record Date
03 Aug 2007 10.0 2.0 10 Aug 2007
Dividend date Dividend amount Dividend type Record date Instrument type
24 Jul 2026 30.0 Final 24 Jul 2026 Equity shares
25 Jul 2025 30.0 Final 25 Jul 2025 Equity shares
02 Aug 2024 30.0 Final 02 Aug 2024 Equity shares
11 Aug 2023 30.0 Final 11 Aug 2023 Equity shares
11 Aug 2022 30.0 Final 12 Aug 2022 Equity shares
17 Aug 2021 20.0 Final 20 Aug 2021 Equity shares
25 Feb 2020 16.0 Interim 26 Feb 2020 Equity shares
14 Aug 2019 16.0 Final 17 Aug 2019 Equity shares
31 Aug 2018 10.0 Final 04 Sep 2018 Equity shares
15 Sep 2017 10.0 Final 19 Sep 2017 Equity shares
17 Mar 2016 10.0 Interim 18 Mar 2016 Equity shares
06 Aug 2015 20.0 Final 10 Aug 2015 Equity shares
31 Jul 2014 20.0 Final 04 Aug 2014 Equity shares
25 Jul 2013 15.0 Final 29 Jul 2013 Equity shares
26 Jul 2012 13.0 Final 30 Jul 2012 Equity shares
16 Jun 2011 10.0 Final 18 Jun 2011 Equity shares
02 Jul 2010 6.0 Final 06 Jul 2010 Equity shares
15 Jun 2009 6.0 Final 17 Jun 2009 Equity shares
26 Jun 2008 4.0 Final 28 Jun 2008 Equity shares
23 Mar 2007 2.0 Interim 26 Mar 2007 Equity shares
11 Aug 2005 0.0 Final 13 Aug 2005 Equity shares
Ex-Date Ex-Bonus Ratio
26 Sep 2015 23 Sep 2015 1:1
01 Aug 2009 30 Jul 2009 1:1
Ex-Date Old FV NEW FV Record Date
03 Aug 2007 10.0 2.0 10 Aug 2007

Top Gainers

Top Losers

About the Company

Divi's Laboratories Limited is a pharmaceutical company and one of the leading manufacturers of active pharmaceutical ingredients and intermediates globally. Headquartered in Hyderabad, the company supplies APIs and intermediates to global pharma companies across generic and specialty segments. 

Divi's Laboratories is listed on the National Stock Exchange under the ticker DIVISLAB and on the Bombay Stock Exchange under the code 532488. The company has large scale manufacturing plants with focus on backwards integration and process chemistry.

The company supplies its products to pharmaceutical companies in India and international markets across multiple regions. 

stock
Trade stocks with ease

Sign-in to trade with your demat account, or set up a new demat account for free

Board Of Directors

Left Arrow
Right Arrow

Similar stocks

Left Arrow
Right Arrow

Frequently Asked Questions

What is the Current Share Price of Divis Laboratories Ltd?

Answer Field

Divis Laboratories Ltd share price is for NSE ₹ 6,638.50 & for BSE ₹ 6,649.50 as on Jun 10 2026 03:30 PM.

What is the Market Cap of Divis Laboratories Ltd Share?

Answer Field

The market cap of Divis Laboratories Ltd for NSE ₹ 0.01 & for BSE ₹ 0.01 as on Jun 10 2026 03:30 PM.

What is the 52 Week High and Low of Divis Laboratories Ltd?

Answer Field

The 52 Week High and Low of Divis Laboratories Ltd for NSE is ₹ 7,071.50 and ₹ 5,636.50 and for BSE is ₹ 7,077.70 and ₹ 5,637.50.

What is 1 year return for Divis Laboratories Ltd?

Answer Field

The 1 year returns on the stock has been 1.80%.

What is the P/E Ratio of Divis Laboratories Ltd Share?

Answer Field

As on Jun 10 2026 03:30 PM the price-to-earnings (PE) ratio for Divis Laboratories Ltd share is 68.80.

What is the PB ratio of Divis Laboratories Ltd Share?

Answer Field

As on Jun 10 2026 03:30 PM, the price-to-book (PB) ratio for Divis Laboratories Ltd share is 629.49.

How to Buy Divis Laboratories Ltd Share?

Answer Field

You can trade in Divis Laboratories Ltd shares with Bajaj Broking by opening a demat account.

How to Buy Divis Laboratories Ltd Share on Bajaj Broking App?

Answer Field

To buy Divis Laboratories Ltd shares on the Bajaj Broking app, follow these steps:

• Login to the Bajaj Broking App

• Click on the Search Icon

• Search “Divis Laboratories Ltd”

• Click on the BUY icon

• Place a buy order specifying the desired quantity of shares.

• Click BUY again to complete the purchase

Who is the CEO of Divi’s Lab?

Answer Field

The CEO of Divi’s Lab oversees the company’s strategic operations and long-term vision. Under their leadership, Divi’s Lab has maintained its strong market position, and their decisions play a crucial role in shaping the company’s performance. The CEO’s leadership directly influences the Divi’s Lab share price as they focus on sustaining growth and expanding the company’s global footprint. Investors closely watch the CEO’s direction as it impacts both the company’s performance and its market valuation.

When was Divi’s Lab established?

Answer Field

Divi’s Lab was established several decades ago, marking its entry into the pharmaceutical sector with a focus on innovation and research. Since its inception, the company has seen steady growth in both its operations and market value. The establishment of Divi’s Lab set the foundation for its current market success, with the Divi’s Lab share price reflecting its long-standing reputation in the industry. Over the years, the company has consistently expanded, becoming a key player in the pharmaceutical market.

What factors influence the Divi’s Lab share price?

Answer Field

Several factors influence the Divi’s Lab share price, including the company’s financial performance, product pipeline, and broader industry trends. Key internal factors such as revenue growth, profitability, and operational efficiency are critical in shaping investor sentiment. External influences like regulatory changes, market conditions, and competitive pressures also play a role. Investors and stakeholders closely monitor these variables to gauge the potential movement of the Divi’s Lab share price, especially in light of evolving market dynamics.

Is Divi’s Lab debt free?

Answer Field

Divi’s Lab maintains a relatively low debt level, positioning itself as a financially stable company. While it may have some debt, it is well-managed and does not pose significant risks to the company’s overall performance. This debt strategy helps maintain investor confidence in the company’s future, positively influencing the Divi’s Lab share price. The company’s balance sheet reflects its prudent financial management, allowing it to focus on growth while maintaining a healthy capital structure.

How has the Divi’s Lab share price performed over the past year?

Answer Field

The Divi’s Lab share price has experienced moderate fluctuations over the past year, largely influenced by the company’s quarterly results and external market conditions. While the price has seen some downturns, it has also shown resilience, particularly during periods of positive financial performance. Overall, the Divi’s Lab share price has remained stable, reflecting the company’s solid position in the pharmaceutical sector. Investors continue to monitor future performance closely to anticipate potential shifts in the share price.

No results found

close-image

Get Free Demat Account*

+91
close-img

Authorise with OTP

Enter the 4-Digit OTP sent to
edit
OTP expires in 00:59
banner-icon

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|

Please Enter Mobile Number

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|